February 27, 2020 / 6:09 AM / a month ago

BRIEF-Acacia Pharma Announces FDA Approval Of BARHEMSYS®

Feb 27 (Reuters) - Acacia Pharma Group PLC:

* ACACIA PHARMA ANNOUNCES US FDA APPROVAL OF BARHEMSYS® (AMISULPRIDE) FOR THE TREATMENT AND PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)

* BARHEMSYS IS ALSO APPROVED FOR PREVENTION OF PONV, EITHER ALONE OR IN COMBINATION WITH AN ANTIEMETIC OF A DIFFERENT CLASS

* AN ESTIMATED 16 MILLION SURGICAL PATIENTS EACH YEAR IN US SUFFER FROM PONV DESPITE RECEIVING PROPHYLAXIS3

* BARHEMSYS IS FIRST AND ONLY ANTIEMETIC TO BE APPROVED FOR RESCUE TREATMENT OF PONV IN PATIENTS WHO HAVE FAILED PRIOR PROPHYLAXIS USING CURRENT STANDARD OF CARE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below